Riskpilot← Back to searchSign inGet full accessDana Genetic A/S
A/SDissolvedCVR 37298182Grusbakken 2DManufacture of pharmaceutical preparations · NACE 2120Est. 2015— employees
Revenue 2021
DKK -47K
-90% vs 2020
EBITDA margin
-274.6%
+127% vs 2020
Equity ratio
-1793.2%
Financial strength
Net profit 2021
DKK 38K
+108% vs 2020
| Revenue | DKK -47K | -90% |
| EBITDA | DKK 129K | +127% |
| Net profit | DKK 38K | +108% |
| Total assets | DKK 144K | -39% |
| Equity | DKK -2,6M | +1% |
| Employees | — | — |
Legal name
Dana Genetic A/S
CVR number
37298182
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10. december 2015
Share capital
DKK 1.500.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2021-09-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af den samlede bestyrelse, af bestyrelsesmedlemmer i forening eller af en direktør alene.
Address
Grusbakken 2D
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | -342 | -639 | -361 | -472 | -47 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1.015 | -687 | -361 | -472 | 129 |
| Depreciation & amort. | -0 | -195 | -164 | -0 | 88 |
| EBIT | -1.015 | -882 | -524 | -472 | 41 |
| Net financials | 1 | -5 | -2 | -3 | -3 |
| Profit before tax | -1.014 | -886 | -526 | -475 | 38 |
| Tax | -148 | -11 | -36 | -0 | -0 |
| Net profit | -866 | -876 | -490 | -475 | 38 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 723 | 295 | 176 | 237 | 144 |
| Equity | -775 | -1.651 | -2.142 | -2.616 | -2.579 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.498 | 1.947 | 2.318 | 2.853 | 2.722 |
| Total debt | 1.498 | 1.947 | 2.318 | 2.853 | 2.722 |
EBITDA margin
12872200.0%
This company
15.8%
Market median
+81469520% vs market
20172021
Equity ratio
-1793.2%
This company
38.2%
Market median
-4794% vs market
20172021
Return on equity
3764600.0%
This company
18.4%
Market median
+20459683% vs market
20172021
Net profit margin
3764600.0%
This company
8.1%
Market median
+46476443% vs market
20172021
Asset turnover
-0.33×
This company
1.12×
Market median
-129% vs market
20172021
Debt / equity
1.06×
This company
0.62×
Market median
-71% vs market
20172021
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HH Chief Executive Officer | Chief Executive Officer | 2015 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Chairman | 2017 – 2023 | |
| Chairman | 2015 – 2017 | |
| Board of Directors | 2017 – 2017 | |
| Board of Directors | 2015 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2016 | |
| Company | 100% | 100% | 2022 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dana Genetic A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans-Ole Hedegaard | Chief Executive Officer | 0 companies |
| Michael Lützhøft Hansen | Chairman | 0 companies |
| Kurt Bækgaard Osther | Chairman | 0 companies |
| Joachim Osther | Board of Directors | 0 companies |
| Kasper Juul Hedegaard | Board of Directors | 0 companies |